NeuroSense Therapeutics (NRSN) Cash & Equivalents (2020 - 2025)

NeuroSense Therapeutics has reported Cash & Equivalents for 6 years, with the latest figure at $166000.0 in Q4 2025.

• Quarterly Cash & Equivalents fell 95.09% year-over-year to $166000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $166000.0 (down 95.09% YoY) and the FY2025 annual result came in at $166000.0, down 95.09% from the prior year.
• Cash & Equivalents fell to $166000.0 in Q4 2025 per NRSN's latest filing, from $666000.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $11.1 million in Q4 2022 and troughed at $166000.0 in Q4 2025.
• A 5-year average of $3.3 million and a median of $2.0 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents surged 1482.69% in 2022, then plunged 95.09% in 2025.
• Over 5 years, Cash & Equivalents stood at $699000.0 in 2021, then soared by 1482.69% to $11.1 million in 2022, then plunged by 76.14% to $2.6 million in 2023, then grew by 27.95% to $3.4 million in 2024, then slumped by 95.09% to $166000.0 in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $166000.0, $666000.0, and $3.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.